A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Mayo Clinic in RochesterRochester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT07570940
- Record updated
- 9 September 2026
- Original description
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.Read full original descriptionShow less
Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.
Inclusion: Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible; Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if coronary artery bypass grafting (CABG) is listed as the primary intervention with other procedures noted as possible additional interventions; Cases will also remain eligible if additional procedures-such as left atrial appendage ligation, MAZE procedure, cryotherapy, or pulmonary vein isolation-are concomitantly listed with the CABG.
Exclusion: Mechanical circulatory support implant or explant; Participants who are pregnant. In accordance with Mayo Clinic's standard cardiac surgery protocol, all women of childbearing potential undergo routine preoperative pregnancy testing. Pregnancy status will therefore be confirmed prior to enrollment. Any participant with a positive pregnancy test will be deemed ineligible and will not be enrolled in the study; Heart and/or lung transplant patients; Active infection/sepsis; Participant has a known allergy to adhesives or hydrogels; Permanent atrial fibrillation; Procedures not requiring cardiopulmonary bypass; Pre-operative anti-arrhythmic use (aside from beta-blockers); Participant has a visible skin injury or broken skin at the location for study device placement; Participant does not have the competency to wear the device for the prescribed patching period; Participant has a neuro-stimulator, as it may disrupt the quality of ECG data; Participants who lack the capacity to provide informed consent will not be approached or enrolled in this study.